Stock IMMUNE DESIGN CORP
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

News Immune Design Corp

Equities

US45252L1035

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
WeissLaw LLP Investigates Immune Design Corp.
PR
Immune Design to Present at Jefferies 2018 London Healthcare Conference
GL
Immune Design Reports Third Quarter 2018 Financial Results and Provides Corporate Update
GL
Immune Design Announces Multiple G100 Presentations at the Society for Immunotherapy of Cancer Meeting (SITC) Annual Meeting
GL
Immune Design to Report Third Quarter 2018 Financial Results and Provide Corporate Update
GL
Immune Design Announces Program Updates & Portfolio Prioritization for G100 and CMB305
GL
Immune Design Reports Second Quarter 2018 Financial Results and Provides Corporate Update
GL
Immune Design to Report Second Quarter 2018 Financial Results and Provide Corporate Update
GL
Immune Design to Host June 4 Cancer Immunotherapy Event in Chicago and Present at Jefferies 2018 Global Healthcare Conference in New York
GL
Immune Design Announces Launch of Web Portal for SYNOVATE Phase 3 Study of CMB305 Immunotherapy in Synovial Sarcoma
GL
Immune Design Reports First Quarter 2018 Financial Results and Provides Corporate Update
GL
Immune Design to Report First Quarter 2018 Financial Results and Provide Corporate Update
GL
Immune Design Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update
GL
Immune Design Reports Data Update for Lead Immunotherapy Programs: Improvement in Survival for CMB305 Monotherapy in Sarcoma and Increased Objective Responses for G100/pembrolizumab Combination in Follicular Lymphoma
GL
Immune Design to Present at Upcoming Investor Conferences
GL
Combination of G100 with KEYTRUDA (pembrolizumab) Triggers Robust Systemic Responses in Follicular NHL Patients
GL
Immune Design to Present at Jefferies 2017 London Healthcare Conference
GL
Immune Design Announces Multiple Presentations at CTOS and SITC Highlighting the Breadth of Existing & Future Product Candidates
GL
Immune Design Reports Third Quarter 2017 Financial Results and Provides Corporate Update
GL
Immune Design to Report Third Quarter 2017 Financial Results & Provide Corporate Update
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. Stock
  4. News Immune Design Corp